Molecular bases of protective immune responses against Botulinum neurotoxin A - How antitoxin antibodies block its action

Critical Reviews in Immunology

Volumn 27, Issue 4, 2007, Pages 319-341

  Atassi, M Zouhair ^a   Dolimbek, Behzod Z ^a   Steward, Lance E ^b   Aoki, K Roger ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ALLERGAN INC   (United States)

Author keywords

Antibodies; Antigenic regions; Binding regions; Botulinum neurotoxin; H chain; Synaptosomes; Synthetic peptides

Indexed keywords

ANTITOXIN; BOTULINUM TOXIN A; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN M ANTIBODY; IODINE 125; NEUROTOXIN; SYNTHETIC PEPTIDE;

AMINO ACID SEQUENCE; ANTIBODY RESPONSE; ANTIGENICITY; BINDING AFFINITY; BOTULISM; BRAIN SYNAPTOSOME; CLOSTRIDIUM BOTULINUM; DYSTONIA; HUMAN; IMMUNE RESPONSE; ISOTOPE LABELING; NECK MUSCLE; NEUROMUSCULAR SYNAPSE; NEUROTOXICITY; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; REVIEW; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BLOCKING; ANTIBODY SPECIFICITY; BINDING SITES, ANTIBODY; BOTULINUM ANTITOXIN; BOTULINUM TOXIN TYPE A; BOTULISM; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PEPTIDE MAPPING; SYNAPTOSOMES; TORTICOLLIS;

EID: 38049061520     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Dickson EC, Shevky R. Botulism studies on the manner in which the toxin of clostridium botulinum acts upon the body. II. the effect on the voluntary nervous system. J Exp Med. 1923;37:327-46.
2. Dickson EC, Shevky R. Botulism studies on the manner in which the toxin of clostridium botulinum acts upon the body. I. the effect upon the autonomic nervous system. J Exp. Med. 1923;37:711-31.
3. Das Gupta, BR, Sugiyama HA. Common subunit structure in clostridium botulinum type A, B and E toxins. Biochem Biophys Res Commun. 1972;48:108-12.
4. Nishiki T, Kamata Y, Nemoto Y, Omori A, Ito T, Takahashi M, Kozaki S. Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes. J Biol Chem. 1994;269:10498-503.
5. Nishiki T, Tokuyama Y, Kamata Y, Nemoto Y, Yoshida A, Sekiguchi M, Takahashi M, Kozaki S. Binding of botulinum type B neurotoxin to Chinese hamster ovary cells transfected with rat synaptotagmin II cDNA. Neuroscience Lett. 1996;208:105-8.
6. Nishiki T, Tokuyama Y, Kamata Y, Nemoto Y, Yoshida A, Sato K, Sekiguchi M, Takahashi M, Kozaki S. The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a, FEBS Lett. 1996;378:253-7.
7. Kozaki S, Miki A, Kamata Y, Ogasawara J, Sakaguchi G. Immunological characterization of papain-induced fragments of Clostridium botulinum type A neurotoxin and interaction of the fragments with brain synaptosomes. Infect Immun. 1989;57:2634-9.
8. Simpson LL. Molecular pharmacology of botulinum toxin and tetanous toxin, Ann Rev Pharmacol Toxicol. 1986;26:427-53.
9. Simpson LL. Peripheral actions of the botulinum toxins. In: Simpson LL, editor. Botulinum neurotoxin and tetanus toxin. New York: Academic Press; 1989. p. 153-78.
10. Bandyopadhyay S, Clark AW, Das Gupta B, Sathyamoorthy V. Role of the heavy and light chains of botulinum neurotoxin in neuromuscular paralysis. J Biol Chem. 1987;262:2660-3.
11. Li L, Singh BR. In vitro translation of type A Clostridium botulinum neurotoxin heavy chain and analysis of its binding to rat synaptosomes. J Prot Chem. 1999;18:89-95.
12. Fu FN, Lomneth RB, Cai S, Singh BR. Role of zinc in the structure and toxic activity of botulinum neurotoxin. Biochemistry. 1998;37:5267-78
13. Li L, Singh BR. Role of zinc binding in type A botulinum neurotoxin light chain's toxic structure. Biochemistry. 2000;39:10581-6.
14. Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry. 2004;75:951-7.
15. Atassi MZ, Oshima M. Structure, activity and immune (T and B cell) recognition of botulinum neurotoxin. Crit Rev Immunol. 1999;19:219-60.
16. Silberstein SD. Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin Pharmacother. 2001;10:1649-54.
17. Borodic G, Johnson E, Goodnough M, Schantz E. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology. 1996;46:26-9.
18. Borodic GE, Acquadro M, Johnson EA. Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Expert Opin Investig Drugs. 2001;10:1531-44.
19. Becker-Wegerich PM, Rauch L, Ruzicka T. Botulinum toxin A: successful decollete rejuvenation. Dermatol Surg. 2002;28:168-71.
20. Binder WJ, Brin MF, Blitzer A, Pogoda JM. Botulinum toxin type A (BOTOX) for treatment of migraine. Dis Mon. 2002;48:323-35.
21. Turton K, Chaddock JA, Acharya KR. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci. 2002;27:552-8.
22. Gui D, Rossi S, Runfola M, Magalini SC. Review article: botulinum toxin in the therapy of gastrointestinal motility disorders. Aliment Pharmacol Therapy. 2003;18:1-16.
23. Göschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H. Botulinum A toxin therapy: Neutralizing and nonneutralizing Abs-therapeutic consequences. Exp Neurol. 1997;147:96-102.
24. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology. 1995;45:1743-6.
25. Jankovic J. Treatment of cervical dystonia with botulinum toxin. Mov Disord. 2004;19(Suppl. 8):S109-15.
26. Atassi MZ. Basic immunological aspects of botulinum toxin therapy. Mov Disord. 2004;19(Suppl 8):S68-S84.
27. Jankovic J, Hunter C, Atassi MZ, Dolimbek BZ, Dolimbek GS, BOS Research Group. Botulinum toxin type B observational study (BOS). Mov Disord. 2005;20(Suppl 10):S31.
28. Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, Comella CL, Gordon M, Riley DE, Sethi K, Singer C, Stacy M, Tarsy D, Atassi MZ. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006;67:2233-5.
29. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003;60:1186-8.
30. Comella CL, Jankovic J, Daggett S, Mordaunt J, Brin MF, Interim results of an observational study of neutralizing antibody formation with the current preparation of botulinum toxin type A treatment for cervical dystonia. Neurology. 2004;62:A511.
31. Agui T, Syuto B, Oguma K, Lida H, Kubo S. Binding of Clostridium botulinum type C neurotoxin to rat brain synaptosomes. J Biochem. 1983;94:521-7.
32. Kitamura M. Binding of botulinum neurotoxin to the synaptosome fraction of rat brain. Naunyn-Schmiedeberg's Arch Pharmacol. 1976;295:171-5.
33. Kozaki S. Interaction of botulinum type A, B and E derivative toxins with synaptosomes of rat brain. Naunyn-Schmiedeberg's Arch Pharmacol. 1979;308:67-70.
34. Kozaki S, Sakaguchi G. Binding to mouse brain synaptosomes of Clostridium botulinum type E derivative toxin before and after tryptic activation. Toxicon. 1982;20:841-6.
35. Kohda T, Kamata Y, Kozaki S. Endocytosis of Clostridium botulinum type B neurotoxin into rat brain synaptosomes. J Vet Med Sci. 2000;62:1133-8.
36. Li L, Singh BR. In vitro translation of type A Clostridium botulinum neurotoxin heavy chain and analysis of its binding to rat synaptosomes. J Prot Chem. 1999;18:89-95.
37. Najib A, Pelliccioni P, Gil C, Aguilera J. Clostridium neurotoxins influence serotonin uptake and release differently in rat brain synaptosomes. J Neurochem. 1999;72:1991-8.
38. Schengrund CL, DasGupta BR, Hughes CA, Ringler NJ. Ganglioside-induced adherence of botulinum and tetanus neurotoxins to adducin. J Neurochem. 1996;66:2556-61.
39. Arribas M, Blasi J, Egea G, Farinas I, Solsona C, Marsal J. High resolution labeling of cholinergic nerve terminals using a specific fully active biotinylated botulinum neurotoxin type A. J Neurosci Res. 1993;36:635-45.
40. Morel N, Israel M, Manaranche R, Mastour-Franchon P. Isolation of pure cholinergic nerve endings from Torpedo electric organ. Evaluation of their metabolic properties. J Cell Biol. 1977;75:43-55.
41. Hirokawa N, Kitamura M. Binding of clostridium botulinum neurotoxin to the presynaptic membrane in the central nervous system. J Cell Biol. 1979;81:43-9.
42. 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J Cell Biol. 1986;103:535-44.
43. Bakry NM, Kamata Y, Simpson LL Expression of botulinum toxin binding sites in xenopus oocytes. Infect Immun. 1997;65:2225-32.
44. Kozaki S, Kamata Y, Watarai S, Nishiki T, Mochida S. Ganglioside GT1b as a complementary receptor component for clostridium botulinum neurotoxins. Microb Pathog. 1998;25:91-9.
45. Dong M, Richards DA, Goodnough MC, Tepp WH, Johnson EA, Chapman ER. Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J Cell Biol. 2003;162:1293-303.
46. Ihara H, Kohda T, Morimoto F, Tsukamoto K, Karasawa T, Nakamura S, Mukamoto M, Kozaki S. Sequence of the gene for clostridium botulinum type B neurotoxin associated with infant botulism, expression of the C-terminal half of heavy chain and its binding activity. Biochim Biophys Acta. 2003;1625:19-26.
47. Jin R, Rummel A, Binz T, Brunger AT. Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature. 2006;444:1092-5.
48. Chai Q, Arndt JW, Dong M, Tepp WH, Johnson EA, Chapman ER, Stevens RC. Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature. 2006;444:1096-100.
49. Veit M. Molecular biology of neurosecretion and its inhibition bu tetanus and botulinum toxins. Berl MunchTierarztl Wochenschr. 1999;112:186-91.
50. Washbourne P, Bortoletto N, Graham ME, Wilson MC, Burgoyne RD, Montecucco C. Botulinum neurotoxin E-insensitive mutants of SNAP-25 fail to bind VAMP but support exocytosis. J Neurochem. 1999;73:2424-33.
51. Gerona RR, Larsen EC, Kowalchyk JA, Martin TF. The C terminus of SNAP25 is essential for Ca(2+)-dependent binding of synaptotagmin to SNARE complexes. J Biol Chem. 2000;275:6328-36.
52. Maruta T, Dolimbek BZ, Aoki KR, Steward LE, Atassi MZ. Mapping of the synaptosome-binding regions on the heavy chain of botulinum neurotoxin A by synthetic overlapping peptides encompassing the entire chain. Protein J. 2004;23:539-52.
53. Rummel A, Mahrhold S, Bigalke H, Binz T. The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol Microbiol. 2004;51:631-43.
54. Atassi MZ, Dolimbek BZ, Hayakari M, Middlebrook JL, Whitney B, Oshima M. Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with anti-toxin antibodies from three host species. J Prot Chem. 1996;15:691-700.
55. Rosenberg JS, Middlebrook JL, Atassi MZ. Localization of the regions on the C-terminal domain of the heavy chain of botulinum toxin A recognized by Tlymphocytes and by antibodies after immunization of mice with pentavalent toxoid. Immunol Investig. 1997;26:491-504.
56. C fragment (residues 855-1296) of the toxin. Mol Immunol. 1997;34:1031-40.
57. C. Immunol Lett. 1998;60:7-12.
58. N-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species - full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A. Protein J. 2004;23:39-52.
59. N domain (residues 449-859) of the heavy chain of botulinum neurotoxin A in two high-responder mouse strains. Immunol Invest. 2005;34:119-42.
60. Dolimbek BZ, Aoki KR, Steward LE, Jankovic J, Atassi MZ. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol. 2007;44:1029-41.
61. Bixler GS Jr, Atassi MZ. Molecular localization of the full profile of the continuous regions recognized by myoglobin primed T-cells using synthetic overlapping peptides encompassing the entire molecule. Immunol Commun. 1983;12:593-603.
62. Bixler GS, Atassi MZ. T cell recognition of myoglobin - localization of the sites stimulating T cell proliferative responses by synthetic overlapping peptides encompassing the entire molecule. J Immunogen. 1984;11:339-53.
63. Kazim AL, Atassi MZ. A novel and comprehensive synthetic approach for the elucidation of protein antigenic structures - determination of the full antigenic profile of the alpha-chain of human haemoglobin. Biochem J. 1980;191:261-4.
64. Kazim AL, Atassi MZ. Structurally inherent antigenic sites. Localization of the antigenic sites of the alpha-chain of human haemoglobin in three host species by a comprehensive synthetic approach. Biochem J. 1982;203:201-8.
65. Atassi MZ. Antigenic structures of proteins - their determination has revealed important aspects of immune recognition and generated strategies for synthetic mimicking or protein binding sites. Eur J Biochem. 1984;145:1-20.
66. Kurisaki JI, Atassi H, Atassi MZ. T-cell recognition of ragweed allergen ra3: localization of the full T-cell recognition profile by synthetic overlapping peptides representing the entire protein chain. Eur J Immuol. 1986;16:236-40.
67. Mulac-Jericevic B, Kurisaki JI, Atassi MZ. Profile of the continuous antigenic regions on the extracellular part of the α-chain of an acetylcholine receptor. Proc Natl Acad Sci USA. 1987;84:3633-7.
68. Ulrich RG, Atassi H, Lutz P, Cresswell P, Atassi MZ. Immune recognition of human major histocompatibility antigens: localization by a comprehensive synthetic strategy of the continuous antigenic sites in the first domain of HLA-DR2 β chain. Eur J Immuol. 1987;17:497-502.
69. Ulrich RG, Atassi MZ. Mapping of the full profile of T-cell allorecognition regions on HLA-DR2β subunit. Eur J Immunol. 1990;20:713-21.
70. Yoshioka N, Atassi MZ. Antigenic structure of human haemoglobin: localization of the antigenic sites of the β-chain in three host species by synthetic overlapping peptides representing the entire chain. Biochem J. 1986;234:441-7.
71. Atassi MZ. Strategies for the localization and synthesis of protein binding sites. In: Tschesche H, editor. Modern methods in protein chemistry. Vol 3. Berlin: de Gruyter; 1988.
72. McCormick DJ, Atassi MZ. Hemoglobin binding with haptoglobin: delineation of the haptoglobin binding site on the α-chain of human hemoglobin. J Prot Chem. 1990;9:735-42.
73. Yoshioka N, Atassi MZ. Haemoglobin binding with haptoglobin: localization of the haptoglobin binding sites on the β-chain of human haemoglobin by synthetic overlapping peptides encompassing the entire chain. Biochem J. 1986;234:453-6.
74. Mulac-Jericevic B, Atassi MZ. Profile of the α-bungarotoxin-binding regions on the extracellular part of the α-chain of torpedo californica acetylcholine receptor. Biochem J. 1987;248:847-52.
75. Mulac-Jericevic B, Manshouri T, Yokoi T, Atassi MZ. The regions of α-neurotoxin binding on the extracellular part of the α-subunit of human acetylcholine receptor. J Prot Chem. 1988;7:173-7.
76. Yoshioka N, Atassi MZ. Subunit interacting surfaces of human hemoglobin in solution. Localization of the α-β subunit interacting surfaces on the α-chain by a comprehensive synthetic strategy. J Prot Chem. 1999;18:179-85.
77. Atassi MZ, Yoshioka N. Mapping of the subunit interacting surfaces of oligomeric proteins in solution by a comprehensive synthetic strategy. J Prot Chem. 1998;17:553-55.
78. Yoshioka N, Atassi MZ. Subunit interacting surfaces of human haemoglobin: localization of the α-β subunit interacting surfaces on the β-chain by a comprehensive synthetic strategy. Biochem J. 1986;234:457-61.
79. Atassi MZ, Mulac-Jericevic B. Mapping the extracellular topography of the α-chain in free and in membrane-bound acetylcholine receptor by antibodies against overlapping peptides spanning the entire extracellular parts of the chain. J Prot Chem. 1994;13:37-47.
80. Atassi MZ, Mulac-Jericevic B, Ashizawa T. Mapping of the polypeptide chain organization of the main extracelluar domain of the α-subunit in membrane-bound acetylcholine receptor by anti-peptide antibodies spanning the entire domain. Adv Expt Med Biol. 1994;347:221-9.
81. Atassi MZ, Smith JA. A proposal for the nomenclature of antigen sites in peptides and proteins. Immunochemistry. 1978;15:609-10.
82. Atassi MZ. Antigenic structure of myoglobin - The complete immunochemical anatomy of a protein and conclusions relating to antigenic structures of proteins. Immunochemistry. 1975;12:423-38.
83. Atassi MZ, Dolimbek GS, Deitiker PR, Aoki KR, Dolimbek BZ. Submolecular recognition profiles in two mouse strains of non-protective and protective antibodies against botulinum neurotoxin A. Mol Immunol. 2005;42:1509-20.
84. Dolimbek BZ, Jankovic J, Atassi MZ. Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response. Immunol Investig. 2002;31:247-62.
85. Okuda K, Christadoss PR, Twining SS, Atassi MZ, David CS. Genetic control of immune response to sperm whale myoglobin in mice. I. T lymphocyte proliferative response under H-2-linked Ir gene control. J Immunol. 1978;121:866-8.
86. Okuda K, Twining SS, David CS, Atassi MZ. Genetic control of immune response to sperm whale myoglobin in mice. II. T lymphocyte proliferative response to the synthetic antigenic sites. J Immunol. 1979;123:182-8.
87. Aoki KR. Immunologic and other properties of therapeutic botulinum toxin serotypes. In: Brin MF, Hallett M, Jankovic J, editors. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 103-13.
88. Atassi MZ. On the enhancement of anti-neurotoxin antibody production by subcomponents HA1 and HA3b of clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology. 2006;152:1891-5.
89. Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol. 1998;5:898-902.
90. Middlebrook JL. Protection strategies against botulinum toxin. Adv Exp Med Biol. 1995;383:93-8.
91. Byrne MP, Smith LA. Development of vaccines for prevention of botulism. Biochimie. 2000;82:955-66.
92. Woodward LA, Arimitsu H, Hirst R, Oguma K. Expression of HC subunits from clostridium types C and D and their evaluation as candidate vaccine antigens in mice. Infect Immunol. 2003;71:2941-4.
93. Koriazova LK, Montal M. Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol. 2003;10:13-8.
94. Li L, Singh BR. Spectroscopic analysis of pH-induced changes in the molecular features of type A botulinum neurotoxin light chain. Biochemistry. 2000;39:6466-74.
95. Maruta T, Dolimbek BZ, Aoki KR, Atassi MZ. Inhibition by human sera of botulinum neurotoxin-A binding to synaptosomes: a new assay for blocking and non-blocking antibodies. J Neurosci Methods. 2006;151:90-6.
96. Rocchia W, Sridharan S, Nicholls A, Alexov E, Chiabrera A, Honig B. Rapid grid-based construction of the molecular surface and the use of induced surface charge to calculate reaction field energies: applications to the molecular systems and geometric objects. J Comp Chem. 2002;23:128-37.